(Albany, United States) As per DelveInsight’s assessment, globally, Intrahepatic Cholangiocarcinoma pipeline constitutes 20+ key companies continuously working towards developing 20+ Intrahepatic Cholangiocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
“Intrahepatic Cholangiocarcinoma Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Intrahepatic Cholangiocarcinoma Market.
The Intrahepatic Cholangiocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ Intrahepatic Cholangiocarcinoma Pipeline Analysis
Some of the key takeaways from the Intrahepatic Cholangiocarcinoma Pipeline Report:
- Intrahepatic Cholangiocarcinoma Companies across the globe are diligently working toward developing novel Intrahepatic Cholangiocarcinoma treatment therapies with a considerable amount of success over the years.
- Intrahepatic Cholangiocarcinoma companies working in the treatment market are TransThera Biosciences, J-Pharma Co., Ltd., Nuvectis Pharma, Inc., Merck, RedHill Biopharma, AnHeart Therapeutics, Tyra Biosciences, Inc., Apollomics and others, are developing therapies for the Intrahepatic Cholangiocarcinoma treatment
- Emerging Intrahepatic Cholangiocarcinoma therapies such as Tinengotinib, Nanvuranlat, NXP 800, and others are expected to have a significant impact on the Intrahepatic Cholangiocarcinoma market in the coming years.
- In February 2024, Beijing InnoCare Pharma Tech Co., Ltd announced results of a Single-Arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of ICP-192 in Subjects With Unresectable or Metastatic Intrahepatic Cholangiocarcinoma With FGFR2 Fusions/Rearrangements Who Have Failed Prior Therapy
- In March 2024, Virogin Biotech Ltd announced results of an Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
- In November 2021, TransThera announced that the US FDA had granted FTD to its Phase II stage product TT-00420 (tinengotinib) for the treatment of patients with CCA who have no standard treatment options. The grant of FTD is primarily based upon the clinical results of TT-00420 in its completed Phase I study, in which nine CCA patients were enrolled and treated with TT-00420 at different dose levels.
Intrahepatic Cholangiocarcinoma Overview
Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive form of liver cancer that originates in the bile ducts within the liver. It accounts for approximately 10-20% of all cholangiocarcinoma cases and is often diagnosed at an advanced stage due to its asymptomatic nature in early phases. Risk factors for iCCA include chronic liver disease, bile duct abnormalities, liver fluke infection, and exposure to certain chemicals. Common symptoms, which appear as the disease progresses, include jaundice, abdominal pain, weight loss, and generalized weakness.
Intrahepatic cholangiocarcinoma Diagnosis typically involves imaging techniques such as ultrasound, CT scans, or MRI, complemented by biopsy and blood tests to confirm the presence of cancer cells and assess liver function. Intrahepatic cholangiocarcinoma Treatment options vary depending on the stage of the disease and may include surgical resection, which offers the best chance for a cure if the tumor is localized. For advanced cases, treatment often involves a combination of chemotherapy, radiation therapy, and targeted therapies aimed at specific genetic mutations within the tumor. Despite these treatments, the prognosis for iCCA remains poor, with a high recurrence rate and limited long-term survival. Research is ongoing to better understand the disease and develop more effective therapeutic strategies.
Get a Free Sample PDF Report to know more about Intrahepatic Cholangiocarcinoma Pipeline Therapeutic Assessment- Intrahepatic Cholangiocarcinoma Drugs in Pipeline
Intrahepatic Cholangiocarcinoma Route of Administration
Intrahepatic Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Intrahepatic Cholangiocarcinoma Molecule Type
Intrahepatic Cholangiocarcinoma Products have been categorized under various Molecule types, such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Intrahepatic Cholangiocarcinoma Pipeline Therapeutics Assessment
- Intrahepatic Cholangiocarcinoma Assessment by Product Type
- Intrahepatic Cholangiocarcinoma By Stage and Product Type
- Intrahepatic Cholangiocarcinoma Assessment by Route of Administration
- Intrahepatic Cholangiocarcinoma By Stage and Route of Administration
- Intrahepatic Cholangiocarcinoma Assessment by Molecule Type
- Intrahepatic Cholangiocarcinoma by Stage and Molecule Type
DelveInsight’s Intrahepatic Cholangiocarcinoma Report covers around 20+ products under different phases of clinical development like-
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Intrahepatic Cholangiocarcinoma product details are provided in the report. Download the Intrahepatic Cholangiocarcinoma pipeline report to learn more about the emerging Intrahepatic Cholangiocarcinoma therapies- Intrahepatic Cholangiocarcinoma Therapeutics Market
Intrahepatic Cholangiocarcinoma Pipeline Analysis:
The Intrahepatic Cholangiocarcinoma pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Intrahepatic Cholangiocarcinoma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Intrahepatic Cholangiocarcinoma Treatment.
- Intrahepatic Cholangiocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Intrahepatic Cholangiocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Intrahepatic Cholangiocarcinoma market.
Download Sample PDF Report to know more about Intrahepatic Cholangiocarcinoma drugs and therapies- Intrahepatic Cholangiocarcinoma Clinical Trials and FDA Approvals
Scope of Intrahepatic Cholangiocarcinoma Pipeline Drug Insight
- Coverage: Global
- Key Intrahepatic Cholangiocarcinoma Companies: TransThera Biosciences, J-Pharma Co., Ltd., Nuvectis Pharma, Inc., Merck, RedHill Biopharma, AnHeart Therapeutics, Tyra Biosciences, Inc., Apollomics and others.
- Key Intrahepatic Cholangiocarcinoma Therapies: Tinengotinib, Nanvuranlat, NXP 800, and others.
- Intrahepatic Cholangiocarcinoma Therapeutic Assessment: Intrahepatic Cholangiocarcinoma current marketed and Intrahepatic Cholangiocarcinoma emerging therapies
- Intrahepatic Cholangiocarcinoma Market Dynamics: Intrahepatic Cholangiocarcinoma market drivers and Intrahepatic Cholangiocarcinoma market barriers
Request for Sample PDF Report for Intrahepatic Cholangiocarcinoma Pipeline Assessment and clinical trials – Intrahepatic Cholangiocarcinoma Drugs in Pipeline
Table of Contents
1. Intrahepatic Cholangiocarcinoma Report Introduction
2. Intrahepatic Cholangiocarcinoma Executive Summary
3. Intrahepatic Cholangiocarcinoma Overview
4. Intrahepatic Cholangiocarcinoma- Analytical Perspective In-depth Commercial Assessment
5. Intrahepatic Cholangiocarcinoma Pipeline Therapeutics
6. Intrahepatic Cholangiocarcinoma Late Stage Products (Phase II/III)
7. Intrahepatic Cholangiocarcinoma Mid Stage Products (Phase II)
8. Intrahepatic Cholangiocarcinoma Early Stage Products (Phase I)
9. Intrahepatic Cholangiocarcinoma Preclinical Stage Products
10. Intrahepatic Cholangiocarcinoma Therapeutics Assessment
11. Intrahepatic Cholangiocarcinoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Intrahepatic Cholangiocarcinoma Companies
14. Intrahepatic Cholangiocarcinoma Key Products
15. Intrahepatic Cholangiocarcinoma Unmet Needs
16 . Intrahepatic Cholangiocarcinoma Market Drivers and Barriers
17. Intrahepatic Cholangiocarcinoma Future Perspectives and Conclusion
18. Intrahepatic Cholangiocarcinoma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Intrahepatic Cholangiocarcinoma Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight